Viewing nowAprogen Risedronate Sodium Tablets 35 mg (Risedronate Sodium 2.5 Hydrate)
Risedronate Sodium 2.5 Hydrate 40.2mg
Tablet · Prescription medication
Aprogen Biologics Co., Ltd.

MFDS item code 200800319 · Notified 2008.01.08 · Insurance code 645207310
Treatment and prevention of osteoporosis in postmenopausal women; treatment of osteoporosis in men
This medication is used for the treatment and prevention of osteoporosis in both postmenopausal women and men.
1. Adults : Administer 35 mg of risedronate sodium orally once weekly. 2. Older adults : No dosage adjustment is necessary in older adults (over 60 years of age), because the bioavailability and pharmacodynamics of this drug are similar to those in younger people. 4. Patients with renal impairment : No dosage adjustment is necessary in patients with a creatinine clearance of 30 mL/min or greater. This drug is contraindicated in patients with severe renal impairment and a creatinine clearance of less than 30 mL/min. ○ Food interferes with the absorption of this drug. To ensure adequate absorption, take it at least 30 minutes before breakfast, or at least 2 hours before or after consuming food or beverages at any other time of day. To help the drug reach the stomach easily and reduce the possibility of esophageal irritation, take it in an upright position with a sufficient amount of plain water (170 ∼ 230 mL). Taking this drug with other beverages, including mineral water, may reduce its absorption. Do not chew or suck this drug because of the possibility of oropharyngeal ulceration. Patients should not lie down for at least 30 minutes after taking it. ○ If a patient forgets to take the drug on the scheduled day, take it the next morning when remembered. Resume the next dose on the originally scheduled day. Do not take 2 tablets on the same day.
The safety and efficacy of this drug in children under 18 years of age have not been established.
This medication is an oral bisphosphonate and is mainly used for the treatment of osteoporosis. It may irritate the upper gastrointestinal mucosa; therefore, caution is required in patients with esophageal disease, gastritis, duodenitis, or ulcers. Severe esophageal adverse reactions such as esophagitis, esophageal ulcers, and esophageal erosion may occur rarely, so if symptoms like difficulty swallowing, pain behind the sternum, or heartburn occur, the medication should be stopped immediately and a doctor should be consulted. This medication must be taken with sufficient water (170-230 mL), and patients should not lie down for at least 30 minutes afterward. Also, food should not be consumed for a period of time before and after taking the medication. Failing to adhere to the administration instructions may greatly increase the risk of esophageal irritation. Furthermore, it's important to take this medication in conjunction with calcium and vitamin D, and patients with metabolic disorders like hypocalcemia, parathyroid dysfunction, or vitamin D deficiency should ensure treatment before use. Women who are pregnant or potentially pregnant, nursing mothers, patients with severe renal impairment, and those with esophageal motility disorders should not use this medication. Bisphosphonate medications have rarely been reported to cause serious side effects such as osteonecrosis of the jaw, atypical femoral fractures, and necrosis of the external auditory canal; if any of these symptoms are suspected, the doctor should be informed immediately. This medication should not be taken with antacids or supplements that contain divalent cations such as calcium, magnesium, iron, or aluminum at the same time, as they can interfere with absorption. Adverse reactions such as fever, myalgia, arthralgia, dyspepsia, diarrhea, and headache may occur during treatment, and if these symptoms are severe or persistent, a consultation with a doctor is necessary. Finally, the safety and efficacy of this medication in children have not been established, and it can be used in the elderly without dose adjustment.
Esophagitis, esophageal ulcer, esophageal erosion, esophageal obstruction, esophageal perforation, bleeding, upper gastrointestinal mucosal irritation, gastric ulcer, duodenal ulcer, dyspepsia, diarrhea, abdominal pain, nausea, constipation, peripheral edema, arthralgia, arthritis, trauma to bones, joint abnormalities, myalgia, bone pain, dizziness, depression, insomnia, bronchitis, sinusitis, rhinitis, pharyngitis, increased coughing, rash, allergic reaction, cataract, urinary tract infection, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, Lhermitte's syndrome, angioedema, blister, skin reaction, osteonecrosis of the external auditory canal, iritis, uveitis, liver dysfunction, jaundice, loss of appetite, asthenia, heartburn, epigastric pain, chest discomfort, palpitations, increased sweating, facial flushing, burning sensation, kidney stones, belching, hematuria, fever, eye pain, acute phase response, fever, influenza-like symptoms, vomiting, hypocalcemia, atypical femoral fracture, jaw necrosis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. The recommended storage temperature is room temperature between 1 degree and 30 degrees Celsius.
Yellow, elongated film-coated tablet
4 tablets/PTP (4 tablets/PTP × 1)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRisedronate Sodium 2.5 Hydrate 40.2mg
Tablet · Prescription medication
Aprogen Biologics Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Austin Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Nexpam Korea Co., Ltd.

Risedronate Sodium 2.5 Hydrate 35mg
Tablet · Prescription medication
Hyutecs Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.2mg
Tablet · Prescription medication
Celix Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Myeongmun Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.